Hook / Thesis
The market just handed investors an $11 billion gift in Celestica (CLS). The stock is trading at roughly $321 a share today while near-term consensus points to outsized revenue and earnings growth driven by AI infrastructure and an expanding HealthTech portfolio. If Celestica simply delivers on the consensus EPS acceleration and the market grants a modestly higher multiple, the valuation gap is large and actionable.
This is a trade idea: buy a disciplined position at or below $321.07 with a clear stop and a target that reflects a conservative re-rating — not a homerun projection. The set-up pairs concrete fundamentals (high ROE, positive free cash flow) with event-driven catalysts that can close the valuation gap.
What Celestica does and why the market should care
Celestica provides end-to-end supply chain solutions and advanced manufacturing for customers in two main segments: Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS). That puts the company squarely in two secular growth buckets investors want exposure to today — AI infrastructure (hyperscale networking, 800G/1.6T switching and AI compute) and HealthTech (medical device manufacturing, diagnostics, diabetes care).
Why care now? Two reasons:
- Demand mix: Customers are increasing orders for high-speed networking and compute assemblies tied to AI infrastructure, where Celestica has meaningful exposure.
- HealthTech runway: The company’s next-generation medical manufacturing and engineering work is a higher-margin, stickier revenue stream as device makers onshore and outsource specialized assembly and testing.
Hard numbers that matter
- Current price: $321.07.
- Market cap: roughly $40.53 billion.
- Trailing EPS: $8.85.
- Free cash flow (trailed): $518.7 million, implying a current FCF yield near 1.3% on enterprise value of about $40.23 billion.
- Return on equity: an impressive 45.02%, signaling strong capital returns on current operations.
- Leverage: debt-to-equity of 0.33, a conservative balance sheet for a capital-intensive EMS business.
- Technicals: RSI ~50 (neutral) and MACD momentum showing bullish histogram pressure — a set-up conducive to a tactical entry.
Valuation framing - where the $11B comes from
At today’s market cap of ~$40.5B the stock is pricing a relatively modest growth scenario. Yet consensus commentary and brokerage revisions point to a sharp acceleration in 2026: one report cites ~64% projected sales growth and ~87% EPS growth for 2026. If EPS grows from $8.85 to roughly $16.56 (8.85 * 1.8711 = 16.56) and the market applies a conservative re-rating to a P/E near 24.6, the implied market cap rises to about $51.5B — roughly an $11B upside versus today.
Put differently: the combination of strong EPS leverage, improved gross margins in high-value segments, and reasonable multiple expansion is enough to bridge the gap without demanding heroic assumptions. That’s the core of this trade idea: earnings growth plus modest multiple expansion, not miracle-level forecasting.
Trade plan (actionable)
| Instrument | Entry | Target | Stop | Direction | Horizon |
|---|---|---|---|---|---|
| CLS | $321.07 | $408.00 | $295.00 | Long | Long term (180 trading days) |
Why this horizon? The path to meaningful re-rating requires time for 2026 results to flow into consensus, for guidance to be updated, and for buy-side positioning to adjust. A 180 trading day window gives enough runway for quarterly beats, margin expansion in ATS/CCS, and renewed analyst multiple compression or expansion to be reflected in the share price.
How to position and manage risk
- Position sizing: size this as a tactical conviction stake — not a full core position. Given the volatility profile in EMS and the presence of short activity, keep initial exposure to a level that allows the stop to be honored without adding under pressure.
- Stop discipline: exit at $295 to protect capital if the thesis breaks (weakness in guidance, sudden loss of a major customer, or material margin compression).
- Add-on plan: consider scaling into strength — add partial exposure on a confirmed quarterly beat and an upward guidance revision that supports the EPS acceleration narrative.
Catalysts (2–5)
- Quarterly earnings that show outsized revenue growth in CCS related to 800G/1.6T networking wins and improved gross margins.
- HealthTech design wins and client certifications that convert to steady, higher-margin backlog.
- Public analyst upgrades and consensus EPS raises — recent brokerage activity has been overwhelmingly positive and could accelerate if the company posts consecutive beats.
- Partnership news or customer wins with hyperscalers and AI customers that provide visible multi-quarter revenue streams.
Risks and counterarguments
- Valuation already elevated. Trading around a mid-30s P/E (snapshot shows P/E near ~33), Celestica is not cheap on trailing numbers. If growth disappoints, multiple compression can be swift and severe.
- Execution risk. Delivering 80% EPS growth is operationally demanding. Misses on margin improvement, delays in customer ramps, or manufacturing snafus would derail the re-rate.
- Customer concentration and ordering volatility. EMS revenues are often lumpy and tied to a handful of hyperscale customers. A single large customer cutback would materially affect near-term results.
- Macro and supply-chain shocks. Recessions, trade disruptions or parts shortages can compress margins even if demand remains healthy.
- Active shorting and implied volatility. Elevated short-volume readings and periodic spikes in short interest highlight that the name can see rapid swings. That volatility can produce stop-hunts and whipsaw risk.
Counterargument: One could reasonably argue the upside is already priced in. The stock’s P/E in the low-to-mid 30s already contains expectations of high growth — meaning even a single quarterly miss could wipe out much of the upside. This is why strict stop discipline and staging size into confirmed fundamental beats is essential.
What would change my mind
- I would exit the idea and reassess if Celestica issues guidance materially below consensus or if management discloses a meaningful loss of a strategic hyperscaler customer.
- A sustained deterioration in margins (falling gross margins for two consecutive quarters) would force me to downgrade the trade thesis.
- Conversely, consecutive quarterly beats, visible multi-quarter backlog, and margin expansion would prompt me to raise the target and convert this tactical position into a larger core holding.
Conclusion
Celestica is a classic earnings-re-rate trade: the company has the businesses, the balance sheet and the consensus growth narrative. At today’s price of roughly $321, the market is underweight the combination of a near-term EPS step-up and the margin benefits of higher-value ATS and CCS work. If management executes and the market grants a modestly higher multiple, the implied upside is meaningful — roughly $11 billion of market cap, or a move toward $408 a share in our plan.
This is not a blind long. It is a measured, time-boxed bet: enter at $321.07, stop at $295, target $408, and plan for a 180 trading day horizon to let earnings and guidance cycle through the tape. Keep position size disciplined and add only after confirmation that growth is realizing in both AI infrastructure and HealthTech.
Key data reference points
- Price: $321.07
- Market cap: $40.53B
- Trailing EPS: $8.85
- Free cash flow (trailing): $518.7M
- ROE: 45.02%
- Leverage (D/E): 0.33
Trade idea timeline: long term (180 trading days). Entry at $321.07, stop $295.00, target $408.00.